Exparel for Pain Control During Care of Rib Fractures

• Status: Withdrawn
• Trial end date: 2017-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is looking at a novel therapy of numbing medication injected directly around the fracture site. The purpose of this study is to determine if the study medication, EXPAREL®, is a viable alternative to current therapies for rib fractures.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Michael Moncure, MD
• Treatments: Bupivacaine

Criteria

Inclusion Criteria:

• patients 18 years of age or older

• patients with three or more rib fractures occurring either unilaterally or bilaterally

• patients who are awake enough to assess pain severity

Exclusion Criteria:

• patients whose pain in other anatomical areas limit rib fracture pain assessment

• patients with a history of hypersensitivity or idiosyncratic reactions or intolerance to any local anesthetic, opioids, or ketorolac

• patients who abuse alcohol or other drug substances

• patients on chronic opioid therapy (taken an opioid 5 of the last 7 days)

• pregnant patients

• severe hepatic impairment

• persistent pain patients requiring 20mg oral morphine equivalent or greater in the 24 hour period prior to sustaining multiple rib fractures

• allergies to common agents used in Exparel (bupivacaine, liposome)

• inability to provide informed consent